Kemin Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kemin Cai has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Xueli Bao
Department of Otorhinolaryngology Head and Neck Surgery, Taizhou People's Hospital, Taizhou 225300, Jiangsu, P.R. China
2 shared publicationsGuan Sun
Department of Neurosurgery, Fourth Affiliated Yancheng Hospital of Nantong University, Yancheng 224000, P.R. China
1 shared publication- Lei Shi
Department of Neurosurgery, The First People’s Hospital of Kunshan Affiliated with Jiangsu University
1 shared publication - Meili Liu
Department of Radiology, Tianjin Huanhu Hospital, Tianjin, 300060, China
1 shared publication Yi Wan
Department of Neurosurgery, Suzhou Kowloon Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Suzhou 215021, P.R. China
1 shared publicationZhimin Wang
Department of Neurosurgery, Suzhou Kowloon Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Suzhou 215021, P.R. China
1 shared publication
Latest Publications
- Open Access
- 12 September 2012
- Published by Spandidos Publications in Oncology Reports
- Vol. 28 (6) , 2101-2106
Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells
Let-7a is frequently downregulated in various types of human cancer including nasopharyngeal carcinoma. However, the underlying mechanism of let-7a action in nasopharyngeal carcinoma remains elusive. In this study, we show that the enhancer of zeste homolog 2 (EZH2) is a direct target of let-7a in human nasopharyngeal carcinoma cells. The inhibition of EZH2 in vitro by let-7a, EZH2 siRNA, attenuated nasopharyngeal carcinoma cell growth, inhibited cell proliferation and induced cell apoptosis. In addition, for each biological process we identified ontology-associated transcripts that significantly correlate with EZH2 expression. Finally, the expression of EZH2 significantly abrogated let-7a-mediated cell proliferation and apoptosis in the nasopharyngeal carcinoma cells. Taken together, our results suggest that let-7a and EZH2 may be potential therapeutic targets for nasopharyngeal carcinoma.
- 12 September 2012
- Published by Spandidos Publications in Oncology Reports
- Vol. 28 (6) , 2101-2106
Open AccessLet-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells
Let-7a is frequently downregulated in various types of human cancer including nasopharyngeal carcinoma. However, the underlying mechanism of let-7a action in nasopharyngeal carcinoma remains elusive. In this study, we show that the enhancer of zeste homolog 2 (EZH2) is a direct target of let-7a in human nasopharyngeal carcinoma cells. The inhibition of EZH2 in vitro by let-7a, EZH2 siRNA, attenuated nasopharyngeal carcinoma cell growth, inhibited cell proliferation and induced cell apoptosis. In addition, for each biological process we identified ontology-associated transcripts that significantly correlate with EZH2 expression. Finally, the expression of EZH2 significantly abrogated let-7a-mediated cell proliferation and apoptosis in the nasopharyngeal carcinoma cells. Taken together, our results suggest that let-7a and EZH2 may be potential therapeutic targets for nasopharyngeal carcinoma.
- Open Access
- 8 August 2011
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 30 (1) , 73
MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma
MiR-106b is frequently up-regulated in various types of human cancer including laryngeal carcinoma. However the underlying mechanism of miR-106b involved in laryngeal carcinoma remains elusive. Here we showed that reduction of miR-106b induced cell cycle G0/G1 arrest by targeting tumor suppressor RB in human laryngeal carcinoma cells. Further, Introducing RB cDNA without 3'UTR abrogated miR-106b-induced cell proliferation. Finally, there was an inverse relationship between RB and miR-106b expression in laryngeal carcinoma tissues. To our knowledge, these data indicate for the first time that miR-106b directly regulate cell cycle by targeting RB in laryngeal carcinoma and that miR-106b could be potential therapeutic approaches for laryngeal carcinoma.
- 8 August 2011
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 30 (1) , 73
Open AccessMiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma
MiR-106b is frequently up-regulated in various types of human cancer including laryngeal carcinoma. However the underlying mechanism of miR-106b involved in laryngeal carcinoma remains elusive. Here we showed that reduction of miR-106b induced cell cycle G0/G1 arrest by targeting tumor suppressor RB in human laryngeal carcinoma cells. Further, Introducing RB cDNA without 3'UTR abrogated miR-106b-induced cell proliferation. Finally, there was an inverse relationship between RB and miR-106b expression in laryngeal carcinoma tissues. To our knowledge, these data indicate for the first time that miR-106b directly regulate cell cycle by targeting RB in laryngeal carcinoma and that miR-106b could be potential therapeutic approaches for laryngeal carcinoma.